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interactionsAbstract The compound 2-{5-[2-(2,6-dichlorophenylamino)benzyl]-4-p-tolyl-4H-1,2,4-triazol-3-
ylthio}acetate has been prepared and characterized by IR, 1H NMR, 13C NMR and mass spectra.
The crystal and molecular structure were further conﬁrmed using single crystal X-ray diffraction.
The crystal structure has been found to be stabilized by intermolecular C–HÆÆÆO interaction gener-
ating bifurcated hydrogen bonds whereas the C–HÆÆÆN interactions generate chain of molecules. The
intramolecular N–HÆÆÆN hydrogen bond forms a ring with S(7) graph-set motif.
ª 2011 Production and hosting by Elsevier B.V. on behalf of King Saud University.
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1,2,4-Triazoles are among the most promising heterocyclic
compounds playing an important role in medicinal, agricul-
tural and industrial ﬁelds. Some of them are used as analytical
reagents for the determination of boron, cobalt and antimony.
A few triazoles ﬁnd synthetic application as halogenatingagents, as activating polymeric reagents and are also used as
photographic reagents. Substituted-1,2,4-triazoles, are among
the various heterocyclic compounds that have received consid-
erable attention during the last two decades for their potential
antibacterial (Andotra et al., 1986), antifungal (Khan et al.,
1987), antiviral (Somorai et al.,1986), antiHIV (Ikizler et al.,
1998), anticancer (Ronghui et al., 2005), diuretic (Shah et al.,
1969), antihypertensive (Emilsson et al., 1987; Kuzmierkiwicz
et al., 1985), anti-inﬂammatory and analgesic (Bozo et al.,
1989; Pignatellol et al., 1991; Mullican et al., 1993), hypoglyce-
mic (Agarwal, 1991), anticonvulsant (Khanum et al., 2004),
and antimycobacterial (Vera et al., 2004) activities. Many anti-
fungal agents containing 1,2,4-triazoles are in clinical use
(Frank et al., 2003; Kelly, 1997). Ribavarin, the antiviral agent
is a synthetic nucleoside derivative containing 1,2,4-triazole
moiety and is active against a wide verity of RNA/DNA virus.
It is used in the treatment of severe lower respiratory infections
caused by RS virus. Guanazole, a very old compound bearing
triazole moiety, is recently found to be active against tumors.
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azole moiety, decreases the estrogen synthesis in the body and
thereby prevents or inhibits the growth of many types of breast
cancer cells that need estrogen to grow.
Various 3-substituted-4-amino-5-mercapto-1,2,4-triazoles
have been reported for their wide spectrum of biological activ-
ities. In recent years, the focus has been on the molecular mod-
iﬁcation of the triazole moiety to obtain a lead molecule with
better biological activity and lesser side effects. Substitutions
have been carried out primarily on the 3rd position of the
1,2,4-triazole ring by substituting groups such thiol, alkylthiol
and alkenylthiol (Eldeen et al., 1991) in order to enhance the
biological activity.
The synthesis of the compound was followed by subsequent
spectroscopic analysis using IR, 1H NMR and 13CNMR tech-
niques to conﬁrm the presence of the supposed ring systems, as
well as the signals for the existence of various protons. The
compound was subjected to single crystal X-ray diffraction
analysis so that its supramolecular structure could be investi-
gated in terms of possible intermolecular interactions.
2. Experimental
2.1. Materials
All chemicals were obtained from a commercial source. Sol-
vents were dried and puriﬁed with known conventional
methods.R COOH
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2.2.1. Physical measurements
Melting points were determined in open capillaries. IR spectra
were recorded on Nicolet FT-IR 410 spectrophotometer,
NMR spectra were recorded on Bruker DRX-300 (300 MHz
FT-NMR) using DMSO as solvent and TMS as internal stan-
dard. Mass spectra were obtained using Shimadzu LCMS
2010A. The title compound was prepared in accordance with
the scheme shown (see Scheme 1).
2.3. Preparation of 2-{5-[2-(2,6-dichlorophenylamino)benzyl]-
4-p-tolyl-4H-1,2,4-triazol-3-ylthio}acetate (6)
2-[2-(2,6-Dichlorophenylamino)phenyl] acetic acid (1) was
converted to ethyl 2-[2-(2,6-dichlorophenylamino)phenyl]ace-
tate (2) by treating with conc. H2SO4 and ethanol. The ester
obtained was converted to 2-[2-(2,6-dichlorophenylami-
no)phenyl]acetohydrazide (3) on treatment with hydrazine
hydrate in absolute ethanol.
1-(2-(2-(2,6-Dichlorophenylamino)phenyl)acetyl)-4-p-tolyl-
thiosemicarbazide (4) was synthesized by condensing p-tolyllis-
othiocyanate with 2-[2-(2,6-dichlorophenylamino)phenyl]
acetohydrazide (3). The base catalyzed intramolecular dehyd-
rative cyclization of 1-(2-(2-(2,6-dichlorophenylamino)phenyl)
acetyl)-4-p-tolylthiosemicarbazide (4) in 2 M sodium hydrox-
ide gave corresponding 5-[2-(2,6-dichlorophenylamino)benzyl]NCS
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of compound 6.
Figure 1 Ortep view of compound 6, showing 50% probability
ellipsoids and the atom numbering scheme.
434 N. Fathima et al.-4-p-tolyl-4H-1,2,4-triazole-3-thiol (5). 5-[2-(2,6-Dichlorophe-
nylamino)benzyl]-4-p-tolyl-4H-1,2,4-triazole-3-thiol (5) when
treated with ethylchloroacetate, in the presence of anhydrous
potassium carbonate yields 2-{5-[2-(2,6-dichlorophenylami-
no)benzyl]-4-p-tolyl-4H-1,2,4-triazol-3-ylthio}acetate (6).
Yield 71% (3.65 g).
2.4. Physical measurements
2.4.1. 2-{5-[2-(2,6-Dichlorophenylamino)benzyl]-4-p-tolyl-4H-
1,2,4-triazol-3-ylthio}acetate (6)
White crystalline solid (DMF), yield 71%, m.p. 158–160 C;
IR (KBr) mcm1: 3250 (–NH) 2980 (CH‚), 1738 (C‚O of
ester, 1583 C–N, 750 (–Cl).
1H NMR (DMSO) d ppm: 1.20–1.27 (t, 3H, alk-CH3), 2.19
(s, 3H, Ar–CH3), 4.01 (s, 2H, Ar–CH2), 4.05 (s, 2H, –SCH2),
4.15–4.22 (q, 2H, –OCH2), 6.38 (s, Ar–NH), 6.5–7.43 (m,
11H, Ar).
13C NMR (DMSO) d ppm: 14.12 (alk-CH3), 21.08 (Ar–
CH3), 28.77 (Ar–CH2), 34.64 (–SCH2), 62.01 (–OCH2),
115.11–150.91 (C of 3Ars), 155.61 (C5 of triazole ring),
160.90 (C3 of triazole ring), 168.28 (C‚O).
MS m/z: (M+1) 528, the other major fragments 523, 499
and 465.
3. X-ray analysis
Single crystals of the compound were obtained from the solvent
DMF. Transparent white plate crystals were selected for X-ray
diffraction analysis. The X-ray diffraction data for compound 6
were collected on a Bruker Smart CCD Area Detector System,
usingMoKa (0.71073 A˚) radiation for the crystal. Intensity data
were collected using a single crystal with dimensions
0.40 · 0.35 · 0.30 mm up to a maximum of 28.40 in the x–a
scan mode. The data were reduced using SAINTPLUS
(Bruker, 1998). The structure was solved by direct methods
using SHELXS97 (Sheldrick, 2008) and difference Fourier syn-
thesis using SHELXL97 (Sheldrick, 2008). The positions and
anisotropic displacement parameters of all non-hydrogen atoms
were included in the full-matrix least-square reﬁnement usingFigure 2 C–HÆÆÆÆÆÆO interaction generating bifurcated bonds from tSHELXL97 (Sheldrick, 2008) and the procedure was carried
out for a few cycles until convergence was reached. A total of
15,519 reﬂections were collected, out of which were 6055
[R(int) = 0.0845] independent reﬂections. The number of reﬂec-
tions satisfying I> 2r (I) criteria were 4013. These were treated
as observed. TheHatomswere placed at the calculated positions
in the ridingmodel approximation (C–H0.93 A˚), with their tem-
perature factors set to 1.2 times those of the equivalent isotropic
temperature factors of the parent atoms. All the other non-H
atoms were reﬁned anisotropically. The R factor for the
observed data ﬁnally converged to R= 0.0658. The maximum
and minimum values of residual electron density were 0.566
and 0.588 eA˚3. Molecular diagrams were generated using
ORTEP (Farrugia, 1997). The mean plane calculation was done
using the program PARST (Nardelli, 1983).wo donors, C4 and C24 to the same acceptor, O2 along ‘b’ axis.
Figure 3 Packing of the molecules in crystal of 6 viewed along ‘a’ axis. Dotted lines indicate, C–HÆÆÆ.N intermolecular interactions.
Table 1 Crystal data and structure reﬁnement.
Empirical formula C25 H24 Cl2 N4 O2 S
Formula weight 515.44
Temperature 293(2) K
Wavelength 0.71073 A˚
Crystal system, space group Orthorhombic, P ca21
Unit cell dimensions
a (A˚) 28.792(10)
b (A˚) 11.012(4)
c (A˚) 7.840(3)
Volume (A˚3) 2485.7(15)
z 4
Calculated density (Mg/m3) 1.377
Absorption coeﬃcient (mm1) 0.376
F(000) 1072
Crystal size 0.40 · 0.35 · 0.30 mm
Theta range for data collection 1.98–28.40
Limiting indices 38 6 h 6 30, 13 6 k 6 14, 10 6
Reﬂections collected/unique 15,519/6055 [R(int) = 0.0845]
Completeness to theta 28.40 98.8%
Reﬁnement method Full-matrix least-squares on F2
Data/restraints/parameters 6055/1/318
Goodness-of-ﬁt on F2 1.301
Final R indices [I> 2r (I)] R1 = 0.0658, wR2 = 0.1284
R indices (all data) R1 = 0.1165, wR2 = 0.1866
Absolute structure parameter 0.82(11)
Largest diﬀ. peak and hole (e A˚3) 0.566 and 0.588
Table 2 Non-bonded interactions and possible hydrogen
bonds (A˚, ) for compound 6. (D-donor; A-acceptor; H-
hydrogen.)
D–H  A D–H H  A D  A D–H  A
N3–H3  N2 0.860(4) 2.256(4) 3.018(6) 147(2)
C4–H4  O2i 0.930(6) 2.963(4) 3.865(7) 163(3)
C24–H24  O2ii 0.930(5) 2.450(4) 3.633(6) 166(3)
C18–H18B  N2iii 0.970(6) 2.688(4) 3.594(8) 155(3)
Symmetry code: (0) x, y, z (i) x, +y+1, +z+1 (ii) x+1, y+2,
+z+1/2 (iii) x, +y, +z1.
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Fig. 1 shows the ORTEP diagram of the molecule with thermal
ellipsoids drawn at 50% probability. Figs. 2 and 3 show hydro-
gen bond interactions and crystal packing of the compound.
The details of crystal data and reﬁnements are given in Table 1.
Table 2 shows the respective hydrogen bond interactions for
compound 6.
Compound 6 comprises 1,2,4-triazole, dichlorophenylami-
no benzyl group and the p-tolyl ring. The non-coplanaritybetween triazole and p-tolyl and that between triazole and
dichlorophenylamino benzyl rings is obvious from the dihedral
angle values of 68.93 and 58.36 respectively. The triazole ring
is essentially planar (La Keya et al., 2006; Buzykin et al., 2008),
the maximum deviation of atoms from their mean statistical
planes being 0.0161 A˚. The bond lengths and angles for the
1,2,4-triazole moiety in the molecule are in good agreement,
within experimental errors, with those observed in other
1,2,4 triazole derivatives (La Keya et al., 2006; Buzykin
et al., 2008). The N(1)–N(2) bond length in the triazole ring
is shorter{1.418(6) A˚} (Gromova et al., 2002) than the distance
characteristics of a single N–N bond (1.47 A˚). The N–C and
N–N distances in the triazole ring vary from 1.30(6) to
1.41(6) A˚. The orientation of thioester group is characterized
by the torsion angle N(1)–C(3)–S(1)–C(16) [22.04(4)].
The molecular structure is primarily stabilized by strong
intramolecular N2–H3ÆÆÆN3 hydrogen bond [N3–
H3 = 0.864(4) A˚, H3ÆÆÆN2= 2.256(4) A˚, N3ÆÆÆN2= 3.018(6) A˚
and the angle N3–H3ÆÆÆN2 = 147.63(2)] leading to the forma-
tion of a seven-membered hydrogen bonded pattern corre-
sponding to graph set S(7) (Bernstein et al., 1995), thus
locking the molecular conformation and eliminating the con-
formational ﬂexibility. The crystal structure is further stabi-
lized by some interesting features that comprise
intermolecular interactions C–HÆÆÆO and C–HÆÆÆN. The C–HÆÆÆO
l 6 10
436 N. Fathima et al.interaction forms a bifurcated bond from two donors C4 and
C24 to the same acceptor O2, linking the molecule in a cohe-
sive manner along ‘b’ axis (Fig. 2). On the other hand the C–
HÆÆÆN interaction results in one dimensional chain along ‘a’
axis (Fig. 3).
5. Conclusion
The synthesis of the substituted-1,2,4-triazole is described.
Additionally, the X-ray analysis was carried out in order to
extrapolate the results observed for structure activity correla-
tions. Weak interactions and supramolecular assembly, involv-
ing several hydrogen bonding interactions of
dichlorophenylamino and triazolo groups with thioester group
have been demonstrated. The structure analysis of this com-
pound provides an insight into the correlation between the
molecular structures and intermolecular interactions in the
compounds for drug development. Hydrogen bonds are the
main non-covalent interactions in the structure of 1,2,4 triazole
derivative and have great inﬂuence on the crystal packing. The
compound has been made with the speciﬁc aim of assessing a
new donor–acceptor-type of hydrogen-bonded interactions to
control the architecture of organic solids for further investiga-
tion of supramolecular assembly in solid-state.
6. Supplementary data
Crystallographic data for the structure (6) reported in this
paper have been deposited with the Cambridge data centre.
The deposition number is CCDC 795601.
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